HIV感染者全球CVD一级预防队列中PCE、PREVENT与SCORE2风险评估比较
基于REPRIEVE试验的全球HIV感染者一级预防队列,纳入7757名有PREVENT和SCORE2计算数据的参与者,比较PCE、PREVENT和SCORE2三种评分对10年ASCVD风险分层及他汀推荐的影响。PCE评估风险最高,PREVENT使38%参与者从较高风险组(≥5%)重分类至较低风险组(<5%),SCORE2使27%的≥50岁者类似下移。PREVENT定义的2.5-5.0%风险组NNT5接近PCE定义的≥5%组。
要点
- PCE评估的10年ASCVD风险中位数最高,SCORE2次之,PREVENT最低。
- PREVENT较PCE使38%参与者从≥5%降至<5%风险组。
- PREVENT定义的2.5-5.0%组NNT5与PCE定义的≥5%组接近。
核心结论
- 基于REPRIEVE的他汀处方指南应考虑到使用PCE以外评分时10年ASCVD风险估计的差异。
研究设计与样本
- 利用REPRIEVE试验的全球HIV感染者一级CVD预防队列,比较应用PCE与PREVENT(按美国指南)或SCORE2(按欧洲指南)的影响。
- 分析队列包含7757名有PREVENT和SCORE2计算数据的参与者。
主要发现
- 10年ASCVD风险估计中位数(Q1,Q3):PCE为4.4%(2.1%,7.1%),SCORE2为3.3%(2.0%,4.9%),PREVENT为2.2%(1.3%,3.3%)。
- 基于PREVENT(对比PCE)的评分使38%的参与者从较高风险组(≥5%)重分类至较低风险组(<5%)。
- 基于SCORE2的评分使27%的年龄≥50岁者类似地从较高风险组重分类至较低风险组。
- 在安慰剂组参与者中,观察到的硬性主要不良心血管事件(MACE)中位发生率/1000人年高于PREVENT预测值,但预测风险极低者除外。
- 使用PREVENT对比PCE,大多数风险组的主要MACE估计累积发生率更高,5年需治疗人数(NNT5)更低;PREVENT定义的2.5-5.0%风险组NNT5为53(95%CI 31-178),PCE定义的≥5%风险组NNT5为47(95%CI 30-109)。
临床怎么用
- 在HIV感染者中应用PREVENT或SCORE2替代PCE时,需注意风险分层下移可能影响他汀启动决策。
- PREVENT定义的2.5-5.0%风险组NNT5与PCE定义的≥5%组接近,提示该组可能仍需考虑他汀治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: REPRIEVE findings catalyzed changes to multiple guidelines directing statin therapy prescribing for people with HIV (PWH). US guidelines use the pooled cohort equation (PCE)-derived 10-year atherosclerotic cardiovascular disease (ASCVD) risk score but may in the future incorporate the new Predicting Risk of CVD EVENTs (PREVENT) score. Meanwhile, European guidelines use Systematic Coronary Risk Evaluation 2 (SCORE2). METHODS: Leveraging Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), we compared effects of applying PCE versus either PREVENT according to US guidelines or SCORE2 according to European guidelines among a global primary CVD prevention cohort of PWH. RESULTS: Analysis cohort included 7757 participants with data for PREVENT and SCORE2 calculation. Ten-year ASCVD risk estimates (median [Q1, Q3]) were highest with PCE (4.4% [2.1%, 7.1%]) versus SCORE2 (3.3% [2.0%, 4.9%]) and PREVENT (2.2% [1.3%, 3.3%]). PREVENT- (vs PCE-) based scoring reclassified 38% of participants from a higher to a lower risk group (≥5% to <5%), while SCORE2-based scoring analogously shifted 27% of those age ≥50 years. Among placebo-assigned participants, median observed incidence of hard major adverse cardiovascular events (MACEs)/1000 person-years (PY) was higher than that predicted by PREVENT, except for those with ultralow predicted risk. The estimated cumulative incidence of primary MACE was higher and 5-year number needed to treat (NNT5) lower for most risk groups using PREVENT versus PCE. The NNT5 for the PREVENT-defined risk group of 2.5-5.0% was close to the NNT5 for the PCE-defined risk group of ≥5% (NNT5[95% CI]: 53 [31, 178] vs 47 [30, 109], respectively). CONCLUSIONS: Statin-prescribing guidelines for PWH based on REPRIEVE should account for differences in 10-year ASCVD risk estimates when scores other than PCE are used. FUNDING: National Institutes of Health, Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare Clinical Trials Registration. REPRIEVE; NCT02344290; https://clinicaltrials.gov/study/NCT02344290.
引用
- Grinspoon SK, Zhao S, Martinez E, et al. Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2. Clin Infect Dis. 2026. PMID: 41004413. doi:10.1093/cid/ciaf542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。